Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Add as a preferred source on Google
NEW YORK, Feb. 27, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ:PETX) securities between March 16, 2015 and February 3, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) therefore, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors regarding the probable timeline for a commercial launch of ENTYCE; and (4) consequently, Aratana’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Aratana you have until April 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/aratana-therapeutics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
